AHA

AHA 2020 – sotagliflozin wins come too late for Lexicon
AHA 2020 – sotagliflozin wins come too late for Lexicon
EP Vantage
Lexicon Pharmaceuticals
sotagliflozin
AHA
heart failure
chronic kidney disease
Flag link:
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
Fierce Pharma
Amarin
Vascepa
AHA
Flag link:
AHA 2020 – look out for the omecamtiv fault lines
AHA 2020 – look out for the omecamtiv fault lines
EP Vantage
AHA
Omecamtiv Mecarbil
Amgen
Cytokinetics
heart failure
Flag link:
AHA to HHS: Stop drugmakers' 'abusive tactics' over 340B discounts
AHA to HHS: Stop drugmakers' 'abusive tactics' over 340B discounts
Beckers Hospital Review
HHS
AHA
Alex Azar
340B
Flag link:
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
Flag link:
AHA: Caladrius single injection helps heart disease that hits women the hardest
AHA: Caladrius single injection helps heart disease that hits women the hardest
Fierce Biotech
Caladrius Biosciences
Women's Health
heart disease
AHA
CLBS16
Syndrome X
Flag link:
AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
Fierce Pharma
AHA
Amgen
Repatha
PCSK9 inhibitor
heart attacks
Flag link:
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
Fierce Pharma
Amarin
Vascepa
AHA
FDA
aterial plaque
Flag link:
AHA: MedCo's PCSK9 rival inclisiran hits LDL
AHA: MedCo's PCSK9 rival inclisiran hits LDL
Fierce Biotech
AHA
The Medicines Company
inclisiran
Flag link:
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
Flag link:
AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata
AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata
Fierce Pharma
Novartis
AHA
Entresto
Flag link:
AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on
AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on
Fierce Pharma
AstraZeneca
Brilinta
Farxiga
AHA
Flag link:
AHA: UnitedHealth report on steep specialty drug costs lets drugmakers off the hook
AHA: UnitedHealth report on steep specialty drug costs lets drugmakers off the hook
Beckers Hospital Review
AHA
UnitedHealth
specialty drugs
drug pricing
Flag link:
Boston Scientific Stands Behind Its Stents in Wake of JAHA Article and FDA Investigation
Boston Scientific Stands Behind Its Stents in Wake of JAHA Article and FDA Investigation
BioSpace
devices
Boston Scientific
FDA
AHA
paclitaxel
stents
Flag link:
Newly vocal union targets Big Pharma's payments to AHA and its leaders
Newly vocal union targets Big Pharma's payments to AHA and its leaders
Fierce Pharma
unions
Big Pharma
AHA
CME
Flag link:
Crestor shines, Vitamin D intrigues at AHA confab
Crestor shines, Vitamin D intrigues at AHA confab
Fierce Pharma
AHA
Crestor
AstraZeneca
Flag link: